CrushSCI.com
提供学术论文选刊润色服务
HemaSphere 期刊封面 医学
返回期刊列表

Review Cycle Records

HemaSphere

Wiley SCIE OA
2026新锐 2区2025中科院 3区2025 JCR Q1
111.3平均天数
101.5中位天数
5最短天数
251最长天数
2302025发文量

Paper Review Records

全部论文审稿周期

20 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接

75 天

DDX41 mutations establish a separate entity in acute myeloid leukemia with distinct survival outcomes

作者Carolin Seeling; Maral Saadati; Daniela Späth; Michael Heuser; Felicitas Thol; Arnold Ganser; Elli Papaemmanuil; Lars Bullinger; Axel Benner; Hartmut Döhner; Konstanze Döhner

作者单位1. Department of Internal Medicine III University Hospital of Ulm Ulm Germany; 2. Division of Biostatistics German Cancer Research Center (DKFZ) Heidelberg Germany; 3. Department of Internal Medicine IV University Hospital Halle (Saale), Martin Luther University Halle‐Wittenberg Halle (Saale) Germany; 4. Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation Hannover Medical School Hannover Germany; 5. Department of Computational Oncology, Epidemiology and Biostatistics Memorial Sloan Kettering Cancer Center New York New York United States of America; 6. Department of Hematology, Oncology and Cancer Immunology Charité‐Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt‐Universität zu Berlin Berlin Germany; 7. German Cancer Consortium (DKTK) Partner Site Berlin Germany; 8. National Center for Tumor Diseases (NCT) Partner Site Berlin Germany

PDF源文件 DOI 网页
139 天

High‐dimensional spectral flow cytometry uncovers progressive T‐cell exhaustion and myeloid cell reprogramming in a CLL mouse model

作者Hannah Briesch; Mariana Coelho; Alessia Floerchinger; Yuliia Borysovych; Nicolas Aubert; Daniel Medina‐Gil; Manina Breitinger; Marc Zapatka; Stella E. Autenrieth; Martina Seiffert

作者单位1. Immune Modulation in Cancer German Cancer Research Center (DKFZ) Heidelberg Germany; 2. Division of Molecular Genetics German Cancer Research Center (DKFZ) Heidelberg Germany; 3. Faculty of Biosciences Heidelberg University Heidelberg Germany; 4. Dendritic Cells in Infection and Cancer German Cancer Research Center (DKFZ) Heidelberg Germany

PDF源文件 DOI 网页
196 天

The machine‐learning classifier ALLCatchR2 identifies 20 T‐ALL subtypes across cohorts and age groups

作者Thomas Beder; Nadine Wolgast; Wencke Walter; Sonja Bendig; Alina M. Hartmann; Malwine J. Barz; Marketa Zaliova; Elisa‐Sophie Reitzel; David Baden; Stefan Schwartz; Nicola Gökbuget; Lennart Kester; Jan Trka; Claudia Haferlach; Monika Brüggemann; Claudia D. Baldus; Martin Neumann; Lorenz Bastian

作者单位1. Medical Department II, Hematology and Oncology University Hospital Schleswig‐Holstein Kiel Germany; 2. University Cancer Center Schleswig‐Holstein (UCCSH) University Hospital Schleswig‐Holstein Kiel Germany; 3. Clinical Research Unit “CATCH ALL” (KFO 5010) Kiel Germany; 4. MLL Munich Leukemia Laboratory Munich Germany; 5. Childhood Leukaemia Investigation Prague, Second Faculty of Medicine Charles University and University Hospital Motol Prague Czech Republic; 6. Department of Hematology, Oncology and Cancer Immunology (Campus Benjamin Franklin) Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität and Humboldt‐Universität zu Berlin Berlin Germany; 7. Department of Medicine II, Hematology/Oncology Goethe University Frankfurt, University Hospital Frankfurt Germany; 8. Princess Maxima Center for Pediatric Oncology Utrecht The Netherlands

PDF源文件 DOI 网页
204 天

Clonotypic characterization defines B‐cell drivers of clonal expansion and intratumor heterogeneity in IgM monoclonal gammopathies

作者David F. Moreno; Ferran Nadeu; Marta Casado‐Peláez; Caterina Mata; Ian Márquez‐López; Marco A. Fernández; Sergi Vaqué; Elena Medina; Helena Llobregat; Marta Garrote; Joan Mañé; Oriol Cardús; Luis Gerardo Rodríguez‐Lobato; Anna de Daniel; María Teresa Cibeira; Theo Gremen Oliveira; Elizaveta Kulaeva; Ester Lozano; Dolors Colomer; Laura Rosiñol; Ruben van Boxtel; Manel Esteller; Carlos Fernández de Larrea

作者单位1. Amyloidosis and Myeloma Unit, Department of Hematology Hospital Clínic de Barcelona, University of Barcelona Barcelona Spain; 2. Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) University of Barcelona Barcelona Spain; 3. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) Madrid Spain; 4. Josep Carreras Leukaemia Research Institute (IJC) University of Barcelona Barcelona Spain; 5. Clinical Flow Cytometry Facility, Biomedical Diagnostic Center Hospital Clínic de Barcelona; 6. Hematopathology Unit, Department of Pathology Hospital Clínic de Barcelona, University of Barcelona Barcelona Spain; 7. Fundação Pró‐Sangue Hemocentro de São Paulo São Paulo Brazil; 8. Princess Máxima Centrum for Pediatric Oncology Utrecht The Netherlands; 9. Oncode Institute Utrecht The Netherlands; 10. Institució Catalana de Recerca i Estudis Avançats (ICREA) Barcelona Spain; 11. Physiological Sciences Department, School of Medicine and Health Sciences University of Barcelona Barcelona Spain; 12. Cancer Epigenetics Group, Sant Pau Research Institute (IR Sant Pau) Barcelona Spain; 13. Department of Medicine, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB) Barcelona Spain

PDF源文件 DOI 网页
85 天

Validation of the advanced‐stage Hodgkin lymphoma international prognostic index (A‐HIPI) in the GHSG HD21 trial

作者Hishan Tharmaseelan; Janina Jablonski; Susan K. Parsons; Angie Mae Rodday; Andrew M. Evens; Josée M. Zijlstra; Alexander Fosså; Daniel Molin; Mark Hertzberg; Felicitas Hitz; Martin Fehr; Richard Greil; Thomas Melchardt; Michael Fuchs; Helen Kaul; Peter Borchmann; Justin Ferdinandus

作者单位1. Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), and German Hodgkin Study Group (GHSG) University of Cologne Cologne Germany; 2. Division of Hematology/Oncology and Institute for Clinical Research and Health Policy Studies Tufts Medical Center Boston Massachusetts United States of America; 3. Division of Blood Disorders Rutgers Cancer Institute New Jersey New Brunswick New Jersey United States of America; 4. Department of Hematology Amsterdam UMC, Vrije Universiteit, Cancer Center Amsterdam Amsterdam The Netherlands; 5. Department of Oncology Oslo University Hospital Oslo Norway; 6. Department of Immunology, Genetics and Pathology Uppsala University Uppsala Sweden; 7. Cancer Immunotherapy Uppsala University Uppsala Sweden; 8. Department of Haematology Prince of Wales Hospital Sydney New South Wales Australia; 9. Australasian Leukaemia Lymphoma Group (ALLG) Melbourne Victoria Australia; 10. Swiss Cancer Institute Competence Center Bern Switzerland; 11. Department of Medical Oncology and Haematology Cantonal Hospital St. Gallen St. Gallen Switzerland; 12. Austrian Group for Medical Tumor Therapy (AGMT) Salzburg Austria; 13. Salzburg Cancer Research Institute – Center for Clinical Cancer and Immunology Trials (SCRI‐CCCIT) Salzburg Austria; 14. Department of Internal Medicine III With Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Cancer Research Laboratory of the Department of Internal Medicine III Paracelsus Medical University Salzburg Austria

PDF源文件 DOI 网页
95 天

Thrombosis in individuals with high oxygen affinity hemoglobin‐associated erythrocytosis: A systematic review and analysis of a national cohort

作者Marie Laloi; Nada Maaziz; Victor Bobée; Philippe Joly; Muriel Giansily‐Blaizot; Mathieu Carpentier; Marie‐Pierre Gourin; Sébastien Trouillier; Claire Barro; Charles Dumontet; Clémence Santana; Matthieu Wemeau; Mathilde Hunault; Damien Luque‐Paz; Serge Pissard; Frédéric Galactéros; François Girodon; Patricia Aguilar‐Martinez; Loïc Garcon; Corentin Orvain

作者单位1. Maladies du Sang, CHU d'Angers Angers France; 2. Service d'Hématologie Biologique, CHU de Dijon Dijon France; 3. Laboratoire d'Hématologie, CHU de Rouen Rouen France; 4. Département de Biopathologie Centre Henri Becquerel Rouen France; 5. Service de Biochimie et de Biologie Moléculaire Hospices Civiles de Lyon Lyon France; 6. Département d'Hématologie Biologique, CHU de Montpellier Montpellier France; 7. Hématologie Clinique et Thérapie Cellulaire, CHU de Limoges Limoges France; 8. Médecine Interne, CH d'Aurillac Aurillac France; 9. Hématologie Biologique, CHU de Grenoble Grenoble France; 10. Service d'Hématologie Biologique et d'Hémostase Clinique Hospices Civiles de Lyon Lyon France; 11. Hématologie, CH de Valence Valence France; 12. Hématologie, CH de Roubaix Roubaix France; 13. Fédération Hospitalo‐Universitaire Grand‐Ouest Acute Leukemia FHU‐GOAL Angers France; 14. Université d'Angers, Inserm UMR 1307, CNRS UMR 6075, Nantes Université, CRCI2NA Angers France; 15. Laboratoire d'Hématologie CHU d'Angers Angers France; 16. INSERM 955/Institut Mondor de Recherche Biomédicale Laboratoire d'Excellence GR‐Ex Créteil France; 17. Département de Génétique Moléculaire Hôpital Mondor, AP‐HP Créteil France; 18. Unité des Maladies Génétiques du Globule Rouge, Centre de Référence des Pathologies du Globule Rouge, APHP, Hôpital Universitaire Henri Mondor Créteil France; 19. Laboratoire d'Hématologie CHU d'Amiens Amiens France

PDF源文件 DOI 网页
87 天

Mitochondrial DNA mutations are associated with impaired oxidative phosphorylation and enhanced imatinib response in chronic myeloid leukemia

作者Ilaria S. Pagani; Vaidehi Krishnan; John F. Ouyang; Chung H. Kok; BeiJun Chen; Kian Leong Lee; Cong M. Pham; Paul Wang; Elyse Page; Phuong Dang; Verity A. Saunders; Jane James; Kelly Lim; Stefano Mangiola; Yingnan Gao; Naranie Shanmuganathan; Agnes Yong; Susan Branford; Charles Chuah; David T. Yeung; Deborah L. White; Vignir G. Helgason; Daniel Thomas; S. Tiong Ong; Timothy P. Hughes; David M. Ross

作者单位1. Precision Cancer Medicine Theme, Blood Cancer Program South Australian Health & Medical Research Institute (SAHMRI) Adelaide South Australia Australia; 2. School of Medicine, College of Health Adelaide University Adelaide South Australia Australia; 3. Australasian Leukaemia and Lymphoma Group Melbourne Victoria Australia; 4. Department of Medical Biology University of Melbourne Melbourne Victoria Australia; 5. Centre for Computational Biology, Program in Cardiovascular and Metabolic Disorders Duke‐NUS Medical School Singapore Singapore; 6. Centre for Cancer Biology University of South Australia Adelaide South Australia Australia; 7. Centre for Computational Biology, Duke‐NUS Medical School Singapore Singapore; 8. Bioinformatics and Computational Biology Division Walter and Eliza Hall Institute of Medical Research Melbourne Victoria Australia; 9. South Australian immunoGENomics Cancer Institute University of Adelaide Adelaide South Australia Australia; 10. Royal Perth Hospital and the University of Western Australia Medical School Perth Western Australia Australia; 11. Department of Haematology Singapore General Hospital and National Cancer Centre Singapore Singapore Singapore; 12. Wolfson Wohl Cancer Research Centre, School of Cancer Sciences University of Glasgow Glasgow United Kingdom; 13. Cancer and Stem Cell Biology Signature Research Programme Duke‐NUS Medical School Singapore Singapore; 14. Department of Haematology Singapore General Hospital Singapore Singapore; 15. Division of Medical Oncology Duke University Medical Center Durham North Carolina United States; 16. Department of Haematology and Genetic Pathology Flinders University and Medical Centre Adelaide South Australia Australia

PDF源文件 DOI 网页
116 天

Differential in vivo tyrosine kinase inhibitor sensitivities of pediatric ABL‐class Ph‐like B‐acute lymphoblastic leukemia

作者Ritul Sharma; Jackson K. Dardis; Huong Anh Mai; Camilo Arenas Merizalde; Cesca van de Ven; Diego A. Bárcenas López; Shubhmita Bhatnagar; Andishe Attarbaschi; Judith M. Boer; Monique L. den Boer; Sarah K. Tasian

作者单位1. Division of Oncology and Center for Childhood Cancer Research Children's Hospital of Philadelphia Philadelphia Pennsylvania United States; 2. Princess Máxima Center for Pediatric Oncology Utrecht The Netherlands; 3. Department of Pediatric Hematology and Oncology St Anna Children's Hospital Vienna Austria; 4. Center for Translational Immunology, University Medical Center Utrecht The Netherlands; 5. Department of Pediatrics University of Pennsylvania School of Medicine Philadelphia Pennsylvania United States; 6. Abramson Cancer Center, University of Pennsylvania School of Medicine Philadelphia Pennsylvania United States

PDF源文件 DOI 网页
163 天

Targeted proteomics reveal histiocytosis‐associated neurodegeneration signatures

作者Egle Kvedaraite; Magda Lourda; Johannes Bastiaan Munting; Matthias Papo; Martin Jädersten; Yoko Shioda; Kenichi Sakamoto; Daniel Martín Muñoz; Panagiotis Andriopoulos; Francesco Pegoraro; Evaldas Laurencikas; Ingrid Kühnle; Joakim Wille; Leonie Naeije; Helena Olkinuora; Indranil Sinha; Daniel W. Hagey; Selma Olsson‐Åkefeldt; Fleur Cohen‐Aubart; Gustaf Österlundh; Mattias Svensson; Ahmed Idbaih; Fredrik Piehl; Kaj Blennow; Henrik Zetterberg; Tatiana Greenwood von Bahr; Désirée Gavhed; Akira Morimoto; Julien Haroche; Jan‐Inge Henter

作者单位1. Department of Pathology and Cancer Diagnostics Karolinska University Hospital Stockholm Sweden; 2. Unit of Molecular Neurobiology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet Stockholm Sweden; 3. The Systems Virology Laboratory, Department of Laboratory Medicine, Division of Clinical Microbiology, Karolinska Institutet Stockholm Sweden; 4. Internal Medicine Department 2, French National Referral Center for Histiocytoses Sorbonne University, Assistance Publique–Hôpitaux de Paris, Pitié‐Salpêtrière Hospital Paris France; 5. Department of Medicine Huddinge, Center for Hematology and Regenerative Medicine, Karolinska Institutet Stockholm Sweden; 6. Department of Hematology Karolinska University Hospital Stockholm Sweden; 7. Children's Cancer Center, National Center for Child health and Development Tokyo Japan; 8. Department of Pediatrics Shinshu University School of Medicine Matsumoto Japan; 9. Department of Neuroradiology and Pediatric Radiology Karolinska University Hospital Solna Stockholm Sweden; 10. Department of Experimental and Clinical Medicine University of Florence Florence Italy; 11. Department of Hematology and Oncology, Meyer Children's Hospital IRCCS Florence Italy; 12. Childhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet Stockholm Sweden; 13. Division of Pediatric Hematology and Oncology Göttingen University Medical Center Göttingen Germany; 14. Childhood Cancer Center Skåne University Hospital Lund Sweden; 15. Princess Máxima Center for Pediatric Oncology Utrecht the Netherlands; 16. Division of Pediatric Hematology‐Oncology and Stem Cell Transplantation, New Children's Hospital Helsinki University Hospital Helsinki Finland; 17. Department of Laboratory Medicine, Division of Biomolecular and Cellular Medicine, Karolinska Institutet Stockholm Sweden; 18. Department of Pediatrics, The Queen Silvia Children's Hospital University of Gothenburg Gothenburg Sweden; 19. Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet Karolinska University Hospital Stockholm Sweden; 20. Sorbonne Université, AP‐HP, Institut du Cerveau ‐ Paris Brain Institute ‐ ICM, Inserm, CNRS Hôpitaux Universitaires La Pitié Salpêtrière ‐ Charles Foix, Service de Neuro‐Oncologie‐Institut de Neurologie Paris France; 21. Department of Neurology Karolinska University Hospital Stockholm Sweden; 22. Neuroimmunology Unit, Center for Molecular Medicine, Karolinska Institutet Stockholm Sweden; 23. Department of Clinical Neuroscience, Karolinska Institutet Stockholm Sweden; 24. Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy University of Gothenburg Mölndal Sweden; 25. Clinical Neurochemistry Laboratory Sahlgrenska University Hospital Gothenburg Sweden; 26. Institute of Neurology University College London London UK; 27. Pediatric Oncology, Astrid Lindgren Children's Hospital Karolinska University Hospital Stockholm Sweden; 28. Division of Pediatrics, Showa Inan General Hospital Komagane Japan

PDF源文件 DOI 网页
138 天

3D ex vivo platform for high‐throughput immunotherapy screening in relapsed/refractory lymphoma patients

作者Fabien Gava; Paul Marcoux; Neus Serrat; Pauline Gravelle; Sonia Quertinmont; Marie Tosolini; Carla Faria; Juan G. Valero; Christina Schniederjohann; Cathy Quelen; Fanny Bouquet; Catia Fonseca; Sylvia Herter; Laura C. Deak; Ron McCord; Eugene Chiang; Peter‐Martin Bruch; Loïc Ysebaert; Patricia Pérez‐Galán; Camille Laurent; Christine Bezombes

作者单位1. Univ Toulouse, INSERM, CRCT Toulouse France; 2. Institut Claudius Regaud ‐ IUCT‐Oncopole, imCORE site Toulouse France; 3. Laboratoire d'Excellence ‘TOUCAN‐2' Toulouse France; 4. Institut Carnot Lymphome CALYM Pierre‐Bénite France; 5. Department of Pathology IUCT‐Oncopole Toulouse France; 6. Fundació Clínic per a la Recerca Biomèdica—Institut d'Investigacions Biomèdiques August Pi i Sunyer Barcelona Spain; 7. Centro de Investigación Biomédica en Red‐Oncología (CIBERONC) Madrid Spain; 8. Oncology Department UNIL‐CHUV Bernhard Gentner laboratory, Agora Research Center Lausanne Switzerland; 9. Department of Hematology Hospital Clínic Barcelona Spain; 10. Department of Hematology, Oncology and Clinical Immunology Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf Düsseldorf Germany; 11. Center for Integrated Oncology Aachen‐Bonn‐Cologne‐Düsseldorf (CIO ABCD) Düsseldorf Germany; 12. Molecular Medicine Partnership Unit (MMPU) Heidelberg Germany; 13. Department of Medicine V Heidelberg University Hospital Heidelberg Germany; 14. F.Hoffmann‐La Roche Zurich Switzerland; 15. Roche Pharma Research and Early Development Roche Innovation Center Zürich Schlieren Switzerland; 16. Genentech San Francisco California USA; 17. Department of Hematology IUCT‐Oncopole Toulouse France

PDF源文件 DOI 网页

Expert Matching · Case Demo

把投稿要求,转成可验证的期刊方案

说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。

CrushSCI 在线

客户询问

我是环境工程专业,需要一篇 SCI,希望 3 个月内见刊。没有基金,也没有大牛挂名,可以投哪些期刊?

CrushSCI回复

可以。先按 90 天时限做可行性筛选,同步查找无基金、无知名作者挂靠的典型论文案例,作为选刊依据。重点核对研究质量与期刊 scope。

拟题建议
《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》

样本口径2026 年最近 5 篇有效论文样本

平均审稿96.4 天

中位数77 天

Contact CrushSCI

联系 CrushSCI

扫码添加微信,或留下手机号/微信号,我们将与你确认稿件阶段、编辑需求和投稿计划。

当前选择:论文编辑服务

也可以预留联系方式

手机号和微信号至少填写一项,仅用于本次咨询联系,不会公开。